Notwithstanding the rise of cancer immunotherapy in the last decade, current B-CLL treatment options usually comprise anti-CD20 monoclonal antibodies (rituximab or obinutuzumab), BTK inhibitors and more recently the Bcl-2 inhibitor venetoclax or ABT-199 [5]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.